Linden Advisors’s Starling Oncology, Inc. Warrant STLNW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-24,316
Closed -$35K 843
2021
Q1
$35K Sell
24,316
-682
-3% -$1.26K ﹤0.01% 713
2020
Q4
$49K Hold
24,998
﹤0.01% 480
2020
Q3
$53K Hold
24,998
﹤0.01% 318
2020
Q2
$37K Buy
+24,998
New +$35.9K ﹤0.01% 258

Other funds holding STLNW

Linden Advisors's STLNW Position: Q2 2021 in Review

Linden Advisors sold out of Starling Oncology, Inc. Warrant (STLNW) in Q2 2021, closing a stake of 24,316 shares — an estimated $35K sold.

Linden Advisors first reported a position in STLNW in Q2 2020 and held it in 4 quarters. The position peaked at $53K in Q3 2020. 26 funds tracked by Wall St. Rank hold STLNW as of Q2 2021.

  • Linden Advisors reported no remaining Starling Oncology, Inc. Warrant position as of Q2 2021 after selling out during the quarter.
  • Linden Advisors sold 24,316 Starling Oncology, Inc. Warrant shares in Q2 2021, an estimated $35K.
  • Linden Advisors first reported a position in Starling Oncology, Inc. Warrant in Q2 2020 and held it in 4 quarters.
  • Linden Advisors's Starling Oncology, Inc. Warrant position peaked at $53K in Q3 2020.
  • 26 funds tracked by Wall St. Rank held Starling Oncology, Inc. Warrant as of Q2 2021.

Based on Linden Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.